- Company
- Pfizer pays an average of 1.1 billion won per person
- by Jung, Sae-Im Mar 15, 2023 05:56am
- It was found that Pfizer Korea Pharmaceutical, which implemented an ERP system through organizational reorganization last year, paid 11.5 billion won as compensation for retirement. It is known that about 10 employees applied for voluntary retirement. It is calculated that each person received an average of 1.1 billion won. According to an a
- Company
- HPV vaccination for males a necessity rather than an option
- by Whang, byung-woo Mar 14, 2023 05:51am
- Whether the national immunization program (NIP) for the human papillomavirus (HPV) vaccine should be extended to cover males remains a hot issue in Korea. With the NIP applied for its use in girls aged 12 years or older, the government extended the program to include those aged 13 to 17 (born between 2004 to 2008) and low-income women aged 18
- Company
- The erectile dysfunction tx market sales are at an all-time
- by Chon, Seung-Hyun Mar 14, 2023 05:51am
- Hanmi Pharmaceutical PalPal Leads for 7 Consecutive Years. Continuation of Dominant System Last year, the domestic erectile dysfunction treatment market grew to the largest ever. Domestic companies' generic products dominated the market, accounting for nearly 90% of the market. According to IQVIA, a drug research institute on the 8th, the size
- Company
- Will the new prostate cancer drug Erleada be reimb in April?
- by Eo, Yun-Ho Mar 14, 2023 05:50am
- Whether the new prostate cancer drug ‘Erleada’ will be listed for reimbursement is gaining industry attention. The drug pricing negotiation period for Janssen Korea’s metastatic hormone-sensitive prostate cancer (mHSPC) treatment Erleada (apalutamide) with the National Health Insurance Service is about to expire this month (March).
- Company
- Eylea makes sole lead in the ₩100B nAMD Tx market
- by Jung, Sae-Im Mar 13, 2023 05:53am
- The sole lead held by ‘Eylea’ in the domestic macular degeneration treatment market has been further solidified last year. Also, Novartis has been aggressively promoting sales of its recently launched new drug ‘Beovu.' With Novartis focusing its sales strategy on Beovu, sales of the company’s lesser priority, 'Lucentis,’ further decli
- Company
- Pharmaceutical companies are fiercely competing to develop
- by Kim, Jin-Gu Mar 13, 2023 05:53am
- In the hyperlipidemia combination drug market of 'statin + ezetimibe', competition to develop a two-drug combination using 'low-dose statin' is intensifying. According to the pharmaceutical industry on the 11th, Yuhan Corporation is developing a combination drug for hyperlipidemia with Ezetimibe added to Atorvastatin 5mg through its subsidiar
- Company
- Gastric cancer is the first immuno-oncology option available
- by Eo, Yun-Ho Mar 13, 2023 05:53am
- In the field of gastric cancer, attention is paid to whether the first immuno-oncology drug insurance benefit registration can be achieved. As a result of the coverage, it is possible to propose the HIRA in April for Opdivo, an immune anticancer drug with PD-1 inhibitory mechanism, from Ono Korea Pharmaceuticals and Korea BMS Pharmaceuticals.
- Company
- GC Pharma begins develop of mRNA flu vaccine candidates
- by Hwang, Jin-joon Mar 10, 2023 05:50am
- Invested in mRNA pilot production facilities in Hwasun Vaccine Plant in Jeollanam-do. GC Pharma announced on the 9th that it will apply Acuitas Therapeutics' Lipid Nano Particle (LNP) technology to develop mRNA flu vaccine candidates in earnest. GC Pharma signed an LNP-related Development and Option Agreement with Acuitas in Canada in April o
- Company
- Myelofibrosis New Drug Inrebic
- by Eo, Yun-Ho Mar 10, 2023 05:50am
- Inrebic, a myelofibrosis treatment option born 10 years after Jakavi, is accelerating its steps toward insurance coverage. As a result of the coverage, BMS Pharmaceutical's myelofibrosis treatment Inrebic is in the process of drug price negotiations with the NHIS. Depending on the negotiation date, it is expected that it will be possible to
- Company
- Enbrel's share is 44% and Herceptin's share is 37%
- by Kim, Jin-Gu Mar 10, 2023 05:50am
- Mabthera, Avastin, and Humira similars also saw a sharp rise in market share new product addition effect. The share of biosimilar products in the domestic market is rapidly expanding. Enbrel biosimilars Etanercept increased its market share from 12% in 2018 to 44% last year. Herceptin similars also expanded from 9% to 37% during the same per
